LAWRENCE Z. FEIGENBAUM, M.D.
To the editor: Dr. Moser's editorial (1) is an important statement on the management of hypertension. I strongly concur that the newer, expensive drugs are not "indicated as initial therapy." However, I am puzzled that reserpine was not considered, since cost containment was the major focus of his editorial Reserpine as a second-step drug should have been mentioned because it is the least expensive hypertensive agent and is well established as being highly effective when added to a thiazide.
To exclude reserpine on the basis of adverse effects does not seem reasonable. Reserpine's commonest adverse effects are nasal congestion and
Learn more about subscription options.
Register Now for a free account.
FEIGENBAUM LZ. Cost Containment and Hypertension. Ann Intern Med. 1988;108:148–149. doi: 10.7326/0003-4819-108-1-148_2
Download citation file:
Published: Ann Intern Med. 1988;108(1):148-149.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only